(BYSI) – Hot Corp. News
-
BeyondSpring (BYSI) Receives CRL from the FDA for Plinabulin NDA for Prevention of Chemotherapy-Induced Neutropenia
-
BeyondSpring (BYSI) DUBLIN-3 Registrational Trial of Plinabulin in Combination with Docetaxel for Treatment of 2nd/3rd Line NSCLC with EGFR Wild Type Met Primary Endpoint
-
Back to BYSI Stock Lookup